John A. Orwin - 20 Apr 2026 Form 4 Insider Report for ANAPTYSBIO, INC (ANAB)

Reporting relationship: Director
Issuer ticker: ANAB
Reported as of: 20 Apr 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 22 Apr 2026, 18:35:46 UTC
Prior SEC filing: 01 Apr 2026
Next SEC filing: 12 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Dan Faga, Attorney-in-Fact

Key filing fact

John A. Orwin filed Form 4 for ANAPTYSBIO, INC (ANAB) on 22 Apr 2026.

Key facts

This page summarizes John A. Orwin's Form 4 filing for ANAPTYSBIO, INC (ANAB).
8 reported transactions and 8 derivative rows are listed below.
Accepted by SEC: 22 Apr 2026, 18:35.

Change

Previous filing in this sequence was filed on 01 Apr 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001477384 Primary reporting owner

Orwin John A

Relationship: Director
Address: C/O ANAPTYSBIO, INC., 10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO
Signature: /s/ Dan Faga, Attorney-in-Fact
Signature date: 22 Apr 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ANAB transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -3,311
Change %: -50%
Price: $0.000000^*
Shares after: 3,311
Date: 20 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,311
Exercise price: $19.50
Footnotes: F1, F2

ANAB transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +3,311
Change %
Price: $0.000000^*
Shares after: 3,311
Date: 20 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,311
Exercise price: $14.29
Footnotes: F1, F2

ANAB transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -10,600
Change %: -50%
Price: $0.000000^*
Shares after: 10,600
Date: 20 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,600
Exercise price: $19.50
Footnotes: F1, F2

ANAB transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +10,600
Change %
Price: $0.000000^*
Shares after: 10,600
Date: 20 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,600
Exercise price: $14.29
Footnotes: F1, F2

ANAB transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -16,510
Change %: -50%
Price: $0.000000^*
Shares after: 16,510
Date: 20 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 16,510
Exercise price: $21.19
Footnotes: F1, F2

ANAB transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +16,510
Change %
Price: $0.000000^*
Shares after: 16,510
Date: 20 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 16,510
Exercise price: $15.53
Footnotes: F1, F2

ANAB transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -8,250
Change %: -50%
Price: $0.000000^*
Shares after: 8,250
Date: 20 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 8,250
Exercise price: $43.91
Footnotes: F1, F3

ANAB transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +8,250
Change %
Price: $0.000000^*
Shares after: 8,250
Date: 20 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 8,250
Exercise price: $32.17
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptysBio shares of common stock in an amount determined in accordance with the Separation Agreement.

Footnote F2

The stock option is fully vested and exercisable.

Footnote F3

The stock option vests as to 1/12 of the total shares monthly commencing on February 6, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.